Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF REORGANISATION
AT CONTROLLING SHAREHOLDER LEVEL

This announcement is made by Sisram Medical Ltd (the "**Company**") on a voluntary basis.

Reference is made to the announcement of the Company dated 8 April 2026 in relation to the proposed reorganisation (the "**Reorganisation**") at controlling shareholder level (the "**Reorganisation Announcement**"), pursuant to which the Securities and Futures Commission granted a waiver from the obligation to make a general offer for the shares in the Company as a result of the Reorganisation. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Reorganisation Announcement.

As disclosed in the Reorganisation Announcement, Ample Up and Chindex, both indirect wholly-owned subsidiaries of Fosun Pharma, had entered into the Agreements to transfer their entire shareholding interest in the Company (representing in aggregate approximately 71.42% of the total issued shares of the Company as at the date of this announcement) to FPI, another indirect wholly-owned subsidiary of Fosun Pharma.

On 22 April 2026, the Board was notified by Fosun Pharma that the Reorganisation has been completed in accordance with the terms of the Agreements. Accordingly, as at the date of this announcement, FPI, an indirect wholly-owned subsidiary of Fosun Pharma, holds 334,504,800 shares of the Company. Fosun Pharma's indirect equity interest in the Company remains unchanged.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Lior Moshe DAYAN
Chairman

Hong Kong, 22 April 2026

As at the date of this announcement, the Board comprises Mr. Lior Moshe DAYAN and Mr. Jiahong LI as executive directors; Mr. Yi LIU, Ms. Rongli FENG and Ms. Caroline Xiaokui JIN as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *for identification purposes only*